<a href="https://www.fiercebiotech.com/biotech/novo-readies-scd-drug-11b-forma-buy-approval-push-after-phase-3-win" hreflang="en">Novo readies SCD drug from $1.1B Forma buyout for approval push after phase 3 win </a>
Novo Nordisk is preparing to submit its drug etavopivat for FDA approval after successful phase 3 trial results, which showed a significant reduction in vaso-occlusive crises in sickle cell disease patients. The drug, acquired through a $1.1 billion buyout of Forma Therapeutics, demonstrated promising efficacy and safety, potentially positioning it as a leading treatment option in a market with limited alternatives.
Novo Nordisk's upcoming FDA submission for etavopivat, a novel oral therapy for sickle cell disease (SCD), highlights a significant advancement in treating this rare blood disorder. The successful phase 3 trial results, demonstrating a 27% reduction in vaso-occlusive crises and a substantial hemoglobin response, position etavopivat as a potential first-in-class treatment. For professionals tracking biotech investments and advancements, this development underscores the value of strategic acquisitions in enhancing a company's therapeutic portfolio, as seen with Novo's $1.1 billion acquisition of Forma Therapeutics.